Ripa, Maria Sejersten

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 416

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL , a randomized trial

McGuire, D. K., Busui, R. P., Deanfield, J., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N., Engelmann, M. D. M., Hovingh, G. K., et al. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 131

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

Leiter, L. A., Bain, S. C., Bhatt, D. L., Buse, J. B., Mazer, C. D., Pratley, R. E., Rasmussen, S., Ripa, M. S., Vrazic, H., & Verma, S. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 45